SCHEMBL7028574

SCHEMBL7028574

O=c1[nH]c(=O)c2c(F)cc(F)cc2[nH]1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR17 Q13304 1/20 0.40
KDM4E B2RXH2 5/20 0.39
ALDH1A1 P00352 4/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
MAPT P10636 2/20 0.38
PDE3B Q13370 2/20 0.38
PDE3A Q14432 2/20 0.38
LMNA P02545 1/20 0.38
CYP19A1 P11511 1/20 0.38
TSHR P16473 1/20 0.38
THPO P40225 1/20 0.38
MTOR P42345 1/20 0.38
HTT P42858 1/20 0.38
HBB P68871 1/20 0.38
PMP22 Q01453 1/20 0.38
CA12 O43570 1/20 0.35
PARP1 P09874 1/20 0.35
CA9 Q16790 1/20 0.35
RXFP1 Q9HBX9 1/20 0.35
HPGD P15428 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29909606 1.00 GPR17 (0.40) GPR17KDM4EALDH1A1SMN1; SMN2MAPT
SCHEMBL29909529 0.81 IDO1 (0.41) KDM4EALDH1A1SMN1; SMN2MAPTLMNA
SCHEMBL23577814 0.81 IDO1 (0.41) KDM4EALDH1A1SMN1; SMN2MAPTLMNA
SCHEMBL7031721 0.76 GRIN2D (0.38) KDM4EALDH1A1SMN1; SMN2MAPTPDE3B
SCHEMBL28703237 0.75 GPR17 (0.43) GPR17KDM4EKMT2A
SCHEMBL29507649 0.75 GPR17 (0.43) GPR17KDM4EKMT2A
SCHEMBL20919828 0.75 DAO (0.43) GPR17KDM4EALDH1A1MAPTPDE3B
SCHEMBL3106487 0.72 FEN1 (0.50) KDM4EALDH1A1SMN1; SMN2MAPTPDE3B
SCHEMBL29567841 0.72 FEN1 (0.50) KDM4EALDH1A1SMN1; SMN2MAPTPDE3B
SCHEMBL24806316 0.71 ALDH1A1 (0.36) KDM4EALDH1A1SMN1; SMN2MAPTPDE3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220324866-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS GILEAD SCIENCES, INC. 2022-10-13 US disclosed
WO-2021130638-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS CARNA BIOSCIENCES, INC. (JP) 2021-07-01 WO disclosed
EP-0878468-B1 Process for producing 1-substituted tetrahydroquinazolines SUMITOMO CHEMICAL CO (JP) 2003-03-19 EP disclosed
EP-0775697-B1 Process for producing 1-substituted tetrahydroquinazolindionen SUMITOMO CHEMICAL CO (JP) 2003-02-12 EP disclosed
US-5994542-A Process for producing 1-substituted tetrahydroquinazolines SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1999-11-30 US disclosed
EP-0878468-A1 Process for producing 1-substituted tetrahydroquinazolines SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1998-11-18 EP disclosed
US-5756738-A Process for producing 1-substituted tetrahydroquinazolines SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1998-05-26 US disclosed
EP-0775697-A1 Process for producing 1-substituted tetrahydroquinazolindionen SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1997-05-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220324866-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS DGKG, DGKB, DGKK GPR17 662/4885KDM4E 1748/4885ALDH1A1 4095/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.